G40.C11

Clinical Causes: Genetic mutations affecting the EPM2A or NHLRC1 gene, leading to abnormal accumulation of insoluble polyglucosans (Lafora bodies) in tissues Inheritance pattern is autosomal recessive, meaning both parents must carry the gene mutation for a child to be affected Lafora disease is typically inherited, with symptoms appearing in adolescence or young adulthood

Key Symptoms: Myoclonus: sudden, brief shock-like movements affecting muscles Seizures that are often resistant to standard medications (intractable) Progressive neurological decline causing cognitive and motor impairment Status epilepticus: prolonged or repeated seizures that do not resolve quickly Visual disturbances, including visual hallucinations or disturbances Ataxia exhibiting difficulty with coordination and balance Behavioral changes, such as irritability or psychiatric symptoms Dementia-like symptoms as the disease progresses

Diagnosis Path: Clinical assessment reviewing neurological symptoms and family history Electroencephalogram (EEG) demonstrating characteristic seizure patterns and myoclonus activity Neuroimaging studies like MRI to assess brain atrophy or other structural changes Skin or muscle biopsy revealing Lafora bodies—clusters of abnormal glycogen stored within cells Genetic testing identifying mutations in EPM2A or NHLRC1 genes Additional laboratory tests to rule out other causes of seizure disorders

Treatment Protocols: Antiepileptic drugs: medications such as valproate, levetiracetam, or clonazepam may help control seizures Tools to manage myoclonus, which can include specific medications or therapies Supportive therapies: physical, occupational, and speech therapy to assist with motor and cognitive function Nutritional support and maintaining overall health to help manage symptoms Regular neurological assessments to monitor progression and adjust treatment plans Addressing behavioral or psychiatric symptoms with counseling or medications as appropriate